Principal Investigator Ii
CurrentDrug discovery and development research focused in novel (switch control) protein kinase inhibitors since 2013, with 4-5 agents in clinical trials. Novel approaches created including targeting a specific conformation (e.g., unactivated forms) with unique enzyme assay design, and slow-binding kinetic characterization at early stage of discovery, to support our so called switch control kinase inhibitor strategy.